钠-葡萄糖共转运蛋白2抑制剂肾脏保护作用的研究进展

Research progress on renal protective effect of sodium-glucose cotransporter 2 inhibitor

目前,慢性肾脏病(CKD)的治疗重点逐渐倾向于肾功能保护。钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)作为一类非胰岛素依赖的新型降糖药,通过参与调节血流动力学、代谢和炎症或纤维化等途径,逐渐显现出肾功能保护益处,拓展了CKD治疗前景。本文就SGLT2i的肾脏结局实验进展、潜在的肾脏保护机制及安全性进行综述。

Currently,the treatment for chronic renal disease(CKD)gradually focuses on the protection of renal function.As a new type of non-insulin-dependent hypoglycemic agent,sodium-glucose transporter 2 inhibitor(SGLT2i)gradually shows the protective benefits of renal function by regulating hemodynamics,metabolism,inflammation or fibrosis,which expands the prospect of CKD treatment.This article reviews the experimental progress of renal outcome,potential renal protection mechanisms and safety of SGLT2i.